



IN-MOL-CELL Infrastructure: Investment to the Core Facilities

IN-MOL-CELL Infrastructure is a new brand for IIMCB's core facilities. It provides world-class support for cutting-edge research and development, ensuring state-of-the-art technological and scientific services. IN-MOL-CELL Infrastructure is designed to cater to both internal and external users.

Development

7 ➔ 10 core facilities

- **Bioinformatics Facility** headed by Anna Hojka-Osińska
Specializes in biological data analysis and computational modeling.
- **Biophysics and Bioanalytics Facility** headed by Krzysztof Skowronek
Offers precise measurement of biophysical properties.
- **Genome Engineering Facility** headed by Olga Gewartowska
Offers a broad range of genetic modifications in mice using CRISPR/Cas9 methodology and other molecular biology services.
- **Microscopy Facility** headed by Tomasz Węgiński
Advanced imaging technologies for cellular and molecular studies.
- **Preclinical Drug Development Facility** headed by Elżbieta Nowak
Provides comprehensive preclinical studies for drug discovery and development, specializing in evaluating new therapeutic strategies.
- **Rodent Facility** headed by Łukasz Majewski
Delivers high-standard housing and care for rodent models, supporting biomedical research by providing a controlled environment for in vivo studies.
- **Zebrafish Core Facility** headed by Magdalena Góra
Supports research using zebrafish models in various fields of biology.
- **Cellular Models and Organoids Facility** (to be established)
Will focus on developing advanced cellular models, including 3D organoids, to study human diseases, offering cutting-edge platforms for drug discovery and basic research.
- **Genomics Facility** (to be established)
Will provide services in high-throughput DNA sequencing, including next-generation sequencing (NGS), to support research in genomics, transcriptomics, and epigenomics.
- **Mass Spectrometry Facility** (to be established)
Will offer advanced mass spectrometry services for the identification and quantification of biomolecules, supporting proteomics, metabolomics, and other biochemical analyses.

Investments and Funding

Total Investment (2023–2029): 89 million PLN

67.7 million PLN for advanced equipment

21.3 million PLN for salaries and training

Acknowledgements

Scan to find proper acknowledgements to IN-MOL-CELL Infrastructure.

Please include them in your publications and posters.



IIMCB IN-MOL-CELL Infrastructure is funded by the European Union – NextGenerationEU under National Recovery and Resilience Plan. IN-MOL-CELL Infrastructure is also funded by the European Union under Horizon Europe (RACE project) and by RACE-PRIME project carried out within the IRAP programme of the Foundation for Polish Science co-financed by the European Union under the European Funds for Smart Economy 2021–2027 (FENG).



Republic
of Poland

Funded by the
European Union
NextGenerationEU



Funded by
the European Union



Republic
of Poland

Co-funded by the
European Union

